# Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

> **NCT00516724** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 189 (actual)

## Conditions studied

- Triple Negative Metastatic Breast Cancer
- Advanced Ovarian Cancer
- Carboplatin
- Paclitaxel

## Interventions

- **DRUG:** KU-0059436 (AZD2281)(PARP inhibitor)
- **DRUG:** Carboplatin
- **DRUG:** KU-0059436 (AZD2281)(PARP inhibitor)
- **DRUG:** Paclitaxel
- **DRUG:** KU-0059436 (AZD2281)(PARP inhibitor)
- **DRUG:** Paclitaxel + Carboplatin

## Key facts

- **NCT ID:** NCT00516724
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-22
- **Primary completion:** 2013-01-04
- **Final completion:** 2024-04-11
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00516724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00516724, "Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00516724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*